Ruspharmtech got a US patent for Alofanib
Company “Russian Pharmaceutical Technologies” (Ruspharmtech) has increased the commercial value of its patent profile by receiving an American patent. The document contains information about originality and innovativeness of company’s development - the drug alofanib, which is the first of class allosteric inhibitor of fibroblast growth factor receptor type 2 (FGFR2) intended for cancer treatment.
- (1888PressRelease) March 28, 2018 - The Russian company «Ruspharmtech» got a US patent for Alofanib - the first of the class allosteric inhibitor of FGFR2 for cancer treatment.
The Company “Russian Pharmaceutical Technologies” (Ruspharmtech) has increased the commercial value of its patent profile by receiving an American patent. The document contains information about originality and innovativeness of company’s development - the drug alofanib, which is the first of class allosteric inhibitor of fibroblast growth factor receptor type 2 (FGFR2).
Alofanib is intended for the targeted therapy of cancer. Various research groups have shown that FGFR2 is the target of therapy for tumors such as stomach cancer, lung cancer, ovarian cancer, cholangiocarcinoma, papillary kidney cancer, triple negative breast cancer and others. The originality of alofanib, described in the patent, consists in selective interaction with the extracellular part of the FGFR2 receptor by the type of monoclonal antibody, that makes the drug highly selective from one hand and devoid of antibody disadvantages on the other. There are no analogs of the drug in the world, which is confirmed by the received Americain patent.
In addition to the US patent, Rusfarmtech already has patents on its territory and in the countries of the Eurasian Patent Convention. Documents confirm exclusive company’s rights, referred to the product development technology - pharmaceutical substance and the way of blocking of the FGFR2 for the pronounced inhibition of tumor growth.
At present Rusfarmtech has finished all preclinical trials and is preparing for a clinical study of the 1b phase of safety and efficacy of alofanib in patients with stomach cancer.
About company Russian Pharmaceutical Technologies
The scientific-research company Russian Pharmaceutical Technologies was founded in 2012 in Saint-Petersburg by the group of scientist with the aim of discovering, studying and commercialization of new drugs and innovative technologies for their production, as well as new methods of treatment in oncology and other fields of medicine. The main project was the development of the allosteric inhibitor FGFR2-alofanib. Since 2012 the company is a resident of the Skolkovo fund. Preclinical studies were implemented with grant support from the foundation.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam